Wang Tom Kai Ming, Abou Hassan Ossama K, Jaber Wael, Xu Bo
Section of Cardiovascular Imaging, Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, United States.
World J Radiol. 2020 Jun 28;12(6):87-100. doi: 10.4329/wjr.v12.i6.87.
Cardiac amyloidosis is a heterogeneous and challenging diagnostic disease with poor prognosis that is now being altered by introduction of new therapies. Echocardiography remains the first-line imaging tool, and when disease is suspected on echocardiography, cardiac magnetic resonance imaging and nuclear imaging play critical roles in the non-invasive diagnosis and evaluation of cardiac amyloidosis. Advances in multi-modality cardiac imaging allowing earlier diagnosis and initiation of novel therapies have significantly improved the outcomes in these patients. Cardiac imaging also plays important roles in the risk stratification of patients presenting with cardiac amyloidosis. In the current review, we provide a clinical and imaging focused update, and importantly outline the imaging protocols, diagnostic and prognostic utility of multimodality cardiac imaging in the assessment of cardiac amyloidosis.
心脏淀粉样变性是一种异质性且诊断具有挑战性的疾病,预后较差,而新疗法的引入正在改变这一现状。超声心动图仍是一线成像工具,当超声心动图怀疑有疾病时,心脏磁共振成像和核成像在心脏淀粉样变性的无创诊断和评估中发挥关键作用。多模态心脏成像技术的进步使早期诊断和启动新疗法成为可能,显著改善了这些患者的治疗效果。心脏成像在心脏淀粉样变性患者的风险分层中也起着重要作用。在本综述中,我们提供了以临床和成像为重点的最新进展,重要的是概述了多模态心脏成像在评估心脏淀粉样变性中的成像方案、诊断和预后效用。